Lv2
200 积分 2023-04-19 加入
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study
24天前
已完结
A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma
24天前
已完结
Aponermin: First Approval
25天前
已完结
Megakaryocytes in myelodysplasia: an immunohistochemical study on bone marrow trephines
29天前
已完结
Direct chemical reprogramming of human cord blood erythroblasts to induced megakaryocytes that produce platelets
3个月前
已完结
Thrombosis in multiple myeloma: mechanisms, risk assessment and management
4个月前
已完结
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma
3个月前
已完结
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
3个月前
已完结
Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL
4个月前
已完结
Correction: Aponermin: First Approval
4个月前
已完结
皖公网安备34019202002308
